BACKGROUND: Preexposure prophylaxis (PrEP) discontinuation rates in clinical trials and demonstration projects have been well characterized; however, little is known about discontinuation in routine public health settings in sub-Saharan Africa. Understanding discontinuation in nonstudy settings is important for establishing expectations for PrEP continuation in national programs and for facilitating effective PrEP scale-up. METHODS: We conducted in-depth interviews with 46 individuals who had initiated PrEP at 25 HIV comprehensive care clinics (CCCs) in central and western Kenya and whose clinic records indicated they had discontinued. RESULTS: Many of our study participants discontinued PrEP when their perceived risk decreased (eg, hiatus or end of a sexual relationship or partner known to be living with HIV became virally suppressed). Others reported discontinuation due to side effects, daily pill burden, preference for condoms, or their partner's insistence. Participant narratives frequently described facility level factors such as stigma-related discomforts with accessing PrEP at CCCs, inconvenient clinic location or operating hours, long wait times, and short refill dates as discouraging factors, suggesting actionable areas for improving PrEP access and continuation. CONCLUSION: Clients frequently make intentional decisions to discontinue PrEP as they weigh different prevention options within the context of complex lives. Many clients will decide to discontinue PrEP when perceiving themselves to be at reduced risk and PrEP counseling must include provisions for addressing seasons of risk. PrEP will not be the right prevention method for everyone, or forever. Expanding PrEP access points and increasing sex-positive messaging may facilitate PrEP being a better option for many.
BACKGROUND: Preexposure prophylaxis (PrEP) discontinuation rates in clinical trials and demonstration projects have been well characterized; however, little is known about discontinuation in routine public health settings in sub-Saharan Africa. Understanding discontinuation in nonstudy settings is important for establishing expectations for PrEP continuation in national programs and for facilitating effective PrEP scale-up. METHODS: We conducted in-depth interviews with 46 individuals who had initiated PrEP at 25 HIV comprehensive care clinics (CCCs) in central and western Kenya and whose clinic records indicated they had discontinued. RESULTS: Many of our study participants discontinued PrEP when their perceived risk decreased (eg, hiatus or end of a sexual relationship or partner known to be living with HIV became virally suppressed). Others reported discontinuation due to side effects, daily pill burden, preference for condoms, or their partner's insistence. Participant narratives frequently described facility level factors such as stigma-related discomforts with accessing PrEP at CCCs, inconvenient clinic location or operating hours, long wait times, and short refill dates as discouraging factors, suggesting actionable areas for improving PrEP access and continuation. CONCLUSION: Clients frequently make intentional decisions to discontinue PrEP as they weigh different prevention options within the context of complex lives. Many clients will decide to discontinue PrEP when perceiving themselves to be at reduced risk and PrEP counseling must include provisions for addressing seasons of risk. PrEP will not be the right prevention method for everyone, or forever. Expanding PrEP access points and increasing sex-positive messaging may facilitate PrEP being a better option for many.
Authors: Kevin M Maloney; Douglas S Krakower; Dale Ziobro; Joshua G Rosenberger; David Novak; Kenneth H Mayer Journal: LGBT Health Date: 2017-05-17 Impact factor: 4.151
Authors: Maria Pyra; Laura K Rusie; Kristin Keglovitz Baker; Andie Baker; Jessica Ridgway; John Schneider Journal: Am J Public Health Date: 2020-01-16 Impact factor: 9.308
Authors: Connie L Celum; Sinead Delany-Moretlwe; Margaret McConnell; Heidi van Rooyen; Linda-Gail Bekker; Ann Kurth; Elizabeth Bukusi; Chris Desmond; Jennifer Morton; Jared M Baeten Journal: J Int AIDS Soc Date: 2015-07-20 Impact factor: 5.396
Authors: Robin Schaefer; Simon Gregson; Elizabeth Fearon; Bernadette Hensen; Timothy B Hallett; James R Hargreaves Journal: Lancet HIV Date: 2019-01-01 Impact factor: 12.767
Authors: G Emmanuel; M Folayan; G Undelikwe; B Ochonye; T Jayeoba; A Yusuf; B Aiwonodagbon; C Bilali; P Umoh; K Ojemeiri; A Kalaiwo Journal: BMC Public Health Date: 2020-01-15 Impact factor: 3.295
Authors: Radhika Sundararajan; Monique A Wyatt; Timothy R Muwonge; Emily E Pisarski; Andrew Mujugira; Jessica E Haberer; Norma C Ware Journal: AIDS Behav Date: 2022-02-08
Authors: Elizabeth M Irungu; Kenneth K Mugwanya; Nelly R Mugo; Elizabeth A Bukusi; Deborah Donnell; Josephine Odoyo; Elizabeth Wamoni; Sue Peacock; Jennifer F Morton; Kenneth Ngure; Mary Mugambi; Irene Mukui; Gabrielle O'Malley; Jared M Baeten Journal: Lancet Glob Health Date: 2021-12 Impact factor: 38.927
Authors: Tiara C Willie; Mauda Monger; Amy Nunn; Trace Kershaw; Jamila K Stockman; Kenneth H Mayer; Philip A Chan; Adaora A Adimora; Leandro A Mena; Deja Knight; Karlye A Philllips; Stefan D Baral Journal: BMC Infect Dis Date: 2021-10-26 Impact factor: 3.090
Authors: Stephanie D Roche; Gena Barnabee; Victor Omollo; Felix Mogaka; Josephine Odoyo; Elizabeth A Bukusi; Jennifer F Morton; Rachel Johnson; Connie Celum; Jared M Baeten; Gabrielle O'Malley Journal: BMC Health Serv Res Date: 2022-03-30 Impact factor: 2.655
Authors: Rutendo Bothma; Cara O'Connor; Jolie Nkusi; Vusi Shiba; Jacob Segale; Luyanda Matsebula; J Joseph Lawrence; L Leigh-Ann van der Merwe; Matthew Chersich; Naomi Hill Journal: J Int AIDS Soc Date: 2022-10 Impact factor: 6.707